XM ඇමරිකා එක්සත් ජනපදයේ පදිංචිකරුවන්ට සේවා සැපයීම සිදු නොකරයි.

XM ඇමරිකා එක්සත් ජනපදයේ පදිංචිකරුවන්ට සේවා සැපයීම සිදු නොකරයි.
G
G

Gilead

පුවත්

Reuters - දින 2කට පෙර

Gilead to donate remdesivir for emergency use against Marburg disease in Rwanda

UPDATE 1-Gilead to donate remdesivir for emergency use against Marburg disease in Rwanda Adds details in paragraph 2, background in paragraphs 4-6 Oct 3 (Reuters) - Gilead Sciences GILD.O said on Thursday it would donate about 5,000 vials of its antiviral drug remdesivir to the Rwanda Medical Supply for emergency use in response to the Marburg virus outbreak.
G
Reuters - දින 2කට පෙර

Gilead to donate remdesivir for emergency use against Marburg disease in Rwanda

Gilead to donate remdesivir for emergency use against Marburg disease in Rwanda Oct 3 (Reuters) - Gilead Sciences GILD.O said on Thursday it would donate about 5,000 vials of its antiviral remdesivir to the Rwanda Medical Supply for emergency use in response to the Marburg virus disease outbreak. Reporting by Mariam Sunny in Bengaluru' Editing by A
G
Reuters - දින 2කට පෙර

Gilead Donates About 5,000 Vials Of Remdesivir For Emergency Use In Response To Marburg Virus Disease In Rwanda

BRIEF-Gilead Donates About 5,000 Vials Of Remdesivir For Emergency Use In Response To Marburg Virus Disease In Rwanda Oct 3 (Reuters) - Gilead Sciences Inc GILD.O : GILEAD DONATES REMDESIVIR FOR EMERGENCY USE IN RESPONSE TO MARBURG VIRUS DISEASE IN RWANDA GILEAD - IT WILL DONATE APPROXIMATELY 5,000 VIALS OF REMDESIVIR TO RWANDA MEDICAL SUPPLY Furth
G
Reuters - දින 2කට පෙර

Rwanda to start vaccine trials for Marburg disease in a few weeks

UPDATE 3-Rwanda to start vaccine trials for Marburg disease in a few weeks Adds detail from WHO in paragraphs 5-6, 8 By Philbert Girinema KIGALI, Oct 3 (Reuters) - Rwanda w ill start cinical trials of experimental vaccines and t reatments f or Marburg disease in the next few weeks , its health minister said on Thursday, t o fight the country's first outbreak of the viral fever, which has so far killed 11 people .
G
Reuters - දින 2කට පෙර

New York Times business news - Oct 3

PRESS DIGEST- New York Times business news - Oct 3 Oct 3 (Reuters) - The following are the top stories on the New York Times business pages. Reuters has not verified these stories and does not vouch for their accuracy. - OpenAI, the company behind ChatGPT, said it had completed a $6.6 billion fund-raising deal that nearly doubles the high-profile company's valuation from just nine months ago.
G
M
Reuters - දින 3කට පෙර

Indian shares set to open lower, tracking Asian peers

INDIA STOCKS-Indian shares set to open lower, tracking Asian peers Oct 3 (Reuters) - Indian shares are likely to open lower on Thursday, tracking other Asian peers, as investors curb their risk appetite amid an escalation of the Middle East conflict. The GIFT Nifty GIFc1 was trading at 25,701.50 points as of 8:13 a.m. IST, indicating that the NSE Nifty 50 .NSEI will open below its previous close of 25,796.90. Worries of a further escalation in the Middle East intensified after Iran fired ballist
G
U
J
Reuters - දින 3කට පෙර

Gilead signs deals with 6 generic drugmakers to sell HIV drug in low-income countries

Gilead signs deals with 6 generic drugmakers to sell HIV drug in low-income countries Oct 2 (Reuters) - Gilead Sciences GILD.O said on Wednesday it has granted royalty-free licenses to six generic drug manufacturers to make and sell cheaper copycat versions of its HIV prevention medicine in 120 low and lower-middle income countries. The U.S.-based drugmaker also plans to provide the companies branded version of the drug, lenacapavir, in 18 countries, such as Botswana, Ethiopia and Kenya, until t
G
Reuters - දින 4කට පෙර

EU withdraws marketing authorisation for Abbvie's hepatitis C drug

UPDATE 2-EU withdraws marketing authorisation for Abbvie's hepatitis C drug Adds background in paragraphs 5 to 7 Oct 1 (Reuters) - The European Medicines Agency said on Tuesday that it has withdrawn the marketing authorisation for Abbvie's ABBV.N hepatitis C drug Exviera at the request of the company. The regulator said it withdrew the authorisation on Sept.
G
Reuters - දින 4කට පෙර

Kailera jumps on weight-loss drug bandwagon with $400 mln early-stage funding

UPDATE 3-Kailera jumps on weight-loss drug bandwagon with $400 mln early-stage funding Adds comments from CEO interview in paragraphs 4 and 8 By Niket Nishant Oct 1 (Reuters) - Kailera Therapeutics launched on Tuesday as the latest startup seeking a slice of the booming market for anti-obesity therapies with a rare $400 million in early-stage funding.
G
Reuters - සති 1කට පෙර

U.S. earnings week ahead

DIARY-U.S. earnings week ahead Sept 27 (Reuters) - Diary of U.S. (.SPX) corporate earnings for the week ahead. ** Please Note - All times given are in U.S. EDT unless otherwise stated ** U.S. EARNINGS Start Date Start Time RIC Company Name Event Name 30-Sep-2024 AMC POCI.O Precision Optics Corporation Inc Q4 2024 Precision Optics Corporation Inc Earnings Release 30-Sep-2024 AMC TRAK Repositrak Inc Q4 2024 Park City Group Inc Earnings Release 30-Sep-2024 10:30 ENS EnerSys EnerSys Tech Talk: Lithi
G
N
P
U
L
M
Reuters - සති 2කට පෙර

FDA Says Gilead Issues Voluntary Nationwide Recall Of One Lot Of Veklury For Injection 100 Mg/Vial

BRIEF-FDA Says Gilead Issues Voluntary Nationwide Recall Of One Lot Of Veklury For Injection 100 Mg/Vial Sept 23 (Reuters) - FDA: FDA: GILEAD ISSUES VOLUNTARY NATIONWIDE RECALL OF ONE LOT OF VEKLURY (REMDESIVIR) FOR INJECTION 100 MG/VIAL DUE TO THE PRESENCE OF A GLASS PARTICLE FDA: GILEAD PRODUCT RECALLED IS LYOPHILIZED FORM OF VEKLURY FOR INJECTIO
G
Reuters - සති 3කට පෙර

U.S. STOCKS Unity Software, Viking Holdings, Adobe

BUZZ-U.S. STOCKS ON THE MOVE-Unity Software, Viking Holdings, Adobe Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes were mixed in choppy trading on Thursday after higher-than-expected producer prices data kept a smaller 25-basis point rate cut by the Fed firmly on the table, while Moderna slumped following a downbeat revenue forecast.
A
G
K
M
U
U
U
D
A
Reuters - සති 3කට පෙර

U.S. STOCKS Gold miners, silver miners, Warner Bros Discovery

BUZZ-U.S. STOCKS ON THE MOVE-Gold miners, silver miners, Warner Bros Discovery Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street was little changed on Thursday after hot producer prices data kept a smaller, 25-basis-point interest-rate cut by the Federal Reserve firmly on the table, while vaccine maker Moderna's shares slumped following a downbeat revenue forecast.
G
K
M
U
U
D
W
A
Reuters - සති 3කට පෙර

Gilead rises as its long-acting HIV drug shows promise compared with daily Truvada

BUZZ-Gilead rises as its long-acting HIV drug shows promise compared with daily Truvada ** Shares of drugmaker Gilead GILD.O rise nearly 2% to $82.55 ** Co says its HIV injectable drug lenacapavir reduced HIV infections by 96% and was superior to daily pill Truvada in second late-stage trial ** The study included cisgender men, transgender men, tra
G
Reuters - සති 3කට පෙර

U.S. Cintas, Sprouts Farmers Market, Voya Financial

U.S. RESEARCH ROUNDUP-Cintas, Sprouts Farmers Market, Voya Financial Sept 12 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Cintas Corp, Sprouts Farmers market and Voya Financial, on Thursday. HIGHLIGHTS * Ally Financial Inc ALLY.N : RBC cuts target price to $40 from $49 * Cintas Corp CTAS.O : CFRA adjusts target price to $170 from $645 to reflect 4-for-1 stock split * Gilead GILD.O : Raymond James raises target pri
C
E
G
L
N
P
S
E
A
D
E
L
Reuters - සති 3කට පෙර

US FDA staff questions confirmatory trial data for Intercept's liver disease drug

UPDATE 2-US FDA staff questions confirmatory trial data for Intercept's liver disease drug Rewrites paragraph 1, adds details from FDA and company's briefing documents in paragraphs 7, 8 and 9 and background in paragraphs 10 and 11 Sept 11 (Reuters) - Staff reviewers at the U.S. Food and Drug Administration said on Wednesday a confirmatory trial did not show the effectiveness of Intercept's liver disease drug, which received the health regulator's accelerated nod in 2016. Under the accelerated p
G
Reuters - මාස 1කට පෙර

U.S. Centerspace, Neurocrine Biosciences, 1-800-Flowers.com

U.S. RESEARCH ROUNDUP-Centerspace, Neurocrine Biosciences, 1-800-Flowers.com Aug 29 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Centerspace, Neurocrine Biosciences and Veeva Systems, on Thursday. HIGHLIGHTS * Air Products APD.N : Berenberg raises target price to $275 from $240 * Centerspace CSR.N : Raymond James raises target price to $82 from $75 * Neurocrine Biosciences Inc NBIX.O : Piper Sandler raises to over
A
G
M
N
N
S
A
D
E
E
A
E
P
Reuters - මාස 1කට පෙර

Nasdaq top and bottom performing stocks at about 12:01 p.m. EDT

BUZZ - Nasdaq top and bottom performing stocks at about 12:01 p.m. EDT Nasdaq 100 .NDX Top Performers Percent Change Gilead Sciences Inc GILD.OQ +2.0% Vertex Pharmaceuticals Inc VRTX.OQ +1.8% Copart Inc CPRT.OQ +1.2% Verisk Analytics Inc VRSK.OQ +1.2% Old Dominion Freight Line Inc ODFL.OQ +1.1% Bottom Performers Percent Change Super Micro Computer Inc SMCI.OQ -25.1% PDD Holdings Inc PDD.OQ -6.3% Arm Holdings PLC ARM.OQ -5.5% Lululemon Athletica Inc LULU.OQ -4.4% Micron Technology Inc MU.OQ -4.3%
G
L
M
V
V
U
P
C
O
Reuters - මාස 1කට පෙර

S&P 500 top and bottom performing stocks at about 12:00 p.m. EDT

BUZZ - S&P 500 top and bottom performing stocks at about 12:00 p.m. EDT S&P 500 .SPX Top Performers Percent Change Insulet Corp PODD.OQ +3.9% Bristol-Myers Squibb Co BMY.N +2.9% Bio Rad Laboratories Inc BIO.N +2.1% Gilead Sciences Inc GILD.OQ +2.0% International Flavors & Fragrances Inc IFF.N +1.9% Bottom Performers Percent Change Super Micro Compu
G
L
M
U
I
Reuters - මාස 1කට පෙර

U.S. Alamo Group, Cognizant, Moderna

CORRECTED-U.S. RESEARCH ROUNDUP- Alamo Group, Cognizant, Moderna Corrects ESS Tech Inc entry to say Deutsche Bank adjusts PT to $9 from $0.90 to reflect 1-for-15 reverse stock split Aug 28 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Alamo Group, Cognizant and Moderna, on Wednesday.
C
G
M
S
U
C
E
P

තත්ත්වයන්

ජනප්‍රිය වත්කම්

වියාචනය: XM Group සමාගම් ක්‍රියාත්මක කිරීම පමණක් වන සේවා සපයන අතර වෙබ් අඩවියේ හෝ වෙබ් අඩවිය හරහා ලබා ගත හැකි අන්තර්ගතය බැලීමට සහ/හෝ භාවිත කිරීමට පුද්ගලයෙකුට ඉඩ සලසමින් අපගේ මාර්ගගත වෙළඳ පහසුකම වෙත ප්‍රවේශය ලබා දෙන අතර වෙනස් කිරීමට හෝ පුළුල් කිරීමට අදහස් නොකරයි. එවැනි ප්‍රවේශය සහ භාවිතය සෑම විටම (i) නියමයන් සහ කොන්දේසි, (ii) අවදානම් අනතුරු ඇඟවීම් සහ (iii) සම්පූර්ණ වියාචනයට යටත් වේ. එබැවින් එවැනි අන්තර්ගතයක් සාමාන්‍ය තොරතුරුවලට වඩා වැඩි යමක් සපයා නොමැත. විශේෂයෙන්ම, අපගේ මාර්ගගත වෙළඳ පහසුකමේ අන්තර්ගතය පෙළඹවීමක් හෝ මූල්‍ය වෙළඳපොළවල කිසිදු ගනුදෙනුවක් සිදු කිරීමට ඉදිරිපත් කිරීමක් නොවන බව කරුණාවෙන් සලකන්න. ඕනෑම මූල්‍ය වෙළඳපොළක වෙළඳාම් කිරීම ඔබේ ප්‍රාග්ධනයට සැලකිය යුතු අවදානමක් එක් කරයි.

අපගේ මාර්ගගත වෙළඳ පහසුකමේ ප්‍රකාශිත සියලු කරුණු අධ්‍යාපනික/තොරතුරුමය අරමුණු සඳහා පමණක් අදහස් කෙරෙන අතර මූල්‍ය, ආයෝජන බදු හෝ වෙළඳ උපදෙස් සහ නිර්දේශයන්; හෝ අපගේ වෙළඳ මිල පිළිබඳ වාර්තාවක්; හෝ ඕනෑම මූල්‍ය උපකරණයක ඉදිරිපත් කිරීමක් හෝ ඒ සඳහා පෙළඹවීමක්; හෝ විශේෂ ඉල්ලීමකින් තොරව ඔබ වෙත ලබා දෙන ලද මූල්‍ය ප්‍රවර්ධනයන් ලෙස නොසැලකිය යුතුය.

ඕනෑම තෙවන පාර්ශවීය අන්තර්ගතයක් මෙන්ම XM විසින් සකසන ලද අන්තර්ගතය එනම් අදහස්, පුවත්, පර්යේෂණ, විශ්ලේෂණ, මිල ගණන් සහ වෙනත් තොරතුරු හෝ මෙම වෙබ් අඩවියේ අන්තර්ගත තෙවන පාර්ශවීය වෙබ් අඩවි සඳහා සබැඳි සාමාන්‍ය වෙළඳපොළ විවරණයක් ලෙස "පවතින පරිදි" සපයා ඇති අතර එහි ආයෝජන උපදෙස් ඇතුළත් නොවේ. ඕනෑම අන්තර්ගතයක් ආයෝජන පර්යේෂණයක් ලෙස අර්ථ දක්වා ඇති ප්‍රමාණයට, ආයෝජන පර්යේෂණයේ ස්වාධීනත්වය ප්‍රවර්ධනය කිරීමට නිර්මාණය කර ඇති නෛතික අවශ්‍යතාවලට අනුකූලව අන්තර්ගතය සකසා නොමැති බවත් එලෙස අරමුණු කර නොමැති බවත් ඔබ සලකා පිළිගත යුතු අතර එබැවින් එය අදාළ නීති සහ රෙගුලාසි යටතේ අලෙවිකරණ සන්නිවේදනයක් ලෙස සලකනු ලැබේ. ඉහත සඳහන් තොරතුරු සලකා මෙතනින් ප්‍රවේශ විය හැකි, ස්වාධීන නොවන ආයෝජන පර්යේෂණ සහ අවදානම් අනතුරු ඇඟවීම පිළිබඳ අපගේ දැනුම්දීම ඔබ කියවා තේරුම් ගෙන ඇති බව සහතික කර ගන්න.

අවදානම් අනතුරු ඇඟවීම: ඔබේ ප්‍රාග්ධනය අවදානමේ පවතී. උත්තෝලිත (ලෙවරේජ්) නිෂ්පාදන සෑම දෙනාටම සුදුසු නොවිය හැකිය. කරුණාකර අපගේ අවදානම් අනාවරණය සලකා බලන්න.